Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

(2019) Ben Klünder et al.   CLINICAL PHARMACOKINETICS

799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve

(2019) Remo Panaccione et al.   GASTROENTEROLOGY

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

(2019) Josef S Smolen et al.   LANCET

Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis

(2018) Yvette N. Lamb et al.   DRUGS

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

(2018) Mark C Genovese et al.   LANCET

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Gerd R Burmester et al.   LANCET

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

(2016) Mohamed-Eslam F. Mohamed et al.   CLINICAL PHARMACOKINETICS

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2016) Mark C. Genovese et al.   Arthritis & Rheumatology

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis

(2014) Kirandeep Kaur et al.   CLINICAL THERAPEUTICS

Selective JAK inhibitors in development for rheumatoid arthritis

(2014) Peter Norman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels

(2014) Pia Isomäki et al.   RHEUMATOLOGY

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

(2012) Kris Vaddi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

Strategies for the Management of Rheumatoid Arthritis

(2012) W.S. Wilkie et al.   ORTHOPEDICS

The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

(2010) Srinivasan Srirangan et al.   Therapeutic Advances in Musculoskeletal Disease